Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome
Introduction Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of...
Saved in:
| Published in | Rheumatology and therapy. Vol. 10; no. 6; pp. 1769 - 1783 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cheshire
Springer Healthcare
01.12.2023
Springer Nature B.V Adis, Springer Healthcare |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Introduction
Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of microvascular manifestations in antiphospholipid antibody (aPL)-positive patients.
Methods
Consecutive patients with persistent aPL positivity referred to Peking Union Medical College Hospital and age- and sex-matched health controls (HCs) were included. Microvascular manifestations included antiphospholipid syndrome (APS) nephropathy, livedo reticularis, valvular lesions, non-stroke central nervous system manifestations, myocarditis, catastrophic APS, and other microvascular manifestations confirmed by pathology, imaging, or clinical diagnosis. Calprotectin was measured by an enzyme-linked immunosorbent assay (ELISA). The cutoff value was defined as mean + 2 standard deviations of HCs. Multivariable logistic regression analysis was used to analyze risk factors. Pearson correlation analysis was used to detect the correlation between calprotectin and other laboratory data.
Results
Of the 466 patients included in the study, 281 (60.3%) patients met the 2006 Sydney Revised Classification Criteria; among the latter, 77.2% were patients with primary APS. The mean age was 39.10 ± 13.05 years old, and 77.0% were female. Thirty-eight age- and sex-matched HCs were included in the study. Serum calprotectin levels were increased in aPL-positive patients compared with HCs (649.66 ± 240.79 vs 484.62 ± 149.37 ng/ml,
p
< 0.001), and were increased in patients with microvascular manifestations compared with patients without (693.03 ± 271.90 vs 639.43 ± 232.06 ng/ml,
p
= 0.044). The cutoff value was 783.36 ng/ml. Ninety-three patients (20.0%) were positive for calprotectin. Calprotectin positivity was independently associated with microvascular manifestations (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.07–3.36) and platelet count (PLT) < 100 (OR 2.04, 95% CI 1.08–3.88). Age (OR 0.98, 95% CI 0.96–1.00), systemic lupus erythematosus (OR 2.08, 95% CI 1.15–3.75), calprotectin positivity (OR 1.83, 95% CI 1.02–3.26), hypertension (OR 2.73, 95% CI 1.36–5.45), hemolytic anemia (OR 2.66, 95% CI 1.13–6.23), and anti-β2GPI antibodies (OR 2.06, 95% CI 1.11–3.83) could independently predict microvascular manifestations in aPL-positive patients. Serum calprotectin negatively correlated with PLT (
R
= − 0.101,
p
= 0.031).
Conclusion
Serum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations. |
|---|---|
| AbstractList | IntroductionMicrovascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of microvascular manifestations in antiphospholipid antibody (aPL)-positive patients.MethodsConsecutive patients with persistent aPL positivity referred to Peking Union Medical College Hospital and age- and sex-matched health controls (HCs) were included. Microvascular manifestations included antiphospholipid syndrome (APS) nephropathy, livedo reticularis, valvular lesions, non-stroke central nervous system manifestations, myocarditis, catastrophic APS, and other microvascular manifestations confirmed by pathology, imaging, or clinical diagnosis. Calprotectin was measured by an enzyme-linked immunosorbent assay (ELISA). The cutoff value was defined as mean + 2 standard deviations of HCs. Multivariable logistic regression analysis was used to analyze risk factors. Pearson correlation analysis was used to detect the correlation between calprotectin and other laboratory data.ResultsOf the 466 patients included in the study, 281 (60.3%) patients met the 2006 Sydney Revised Classification Criteria; among the latter, 77.2% were patients with primary APS. The mean age was 39.10 ± 13.05 years old, and 77.0% were female. Thirty-eight age- and sex-matched HCs were included in the study. Serum calprotectin levels were increased in aPL-positive patients compared with HCs (649.66 ± 240.79 vs 484.62 ± 149.37 ng/ml, p < 0.001), and were increased in patients with microvascular manifestations compared with patients without (693.03 ± 271.90 vs 639.43 ± 232.06 ng/ml, p = 0.044). The cutoff value was 783.36 ng/ml. Ninety-three patients (20.0%) were positive for calprotectin. Calprotectin positivity was independently associated with microvascular manifestations (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.07–3.36) and platelet count (PLT) < 100 (OR 2.04, 95% CI 1.08–3.88). Age (OR 0.98, 95% CI 0.96–1.00), systemic lupus erythematosus (OR 2.08, 95% CI 1.15–3.75), calprotectin positivity (OR 1.83, 95% CI 1.02–3.26), hypertension (OR 2.73, 95% CI 1.36–5.45), hemolytic anemia (OR 2.66, 95% CI 1.13–6.23), and anti-β2GPI antibodies (OR 2.06, 95% CI 1.11–3.83) could independently predict microvascular manifestations in aPL-positive patients. Serum calprotectin negatively correlated with PLT (R = − 0.101, p = 0.031).ConclusionSerum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations. Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of microvascular manifestations in antiphospholipid antibody (aPL)-positive patients. Consecutive patients with persistent aPL positivity referred to Peking Union Medical College Hospital and age- and sex-matched health controls (HCs) were included. Microvascular manifestations included antiphospholipid syndrome (APS) nephropathy, livedo reticularis, valvular lesions, non-stroke central nervous system manifestations, myocarditis, catastrophic APS, and other microvascular manifestations confirmed by pathology, imaging, or clinical diagnosis. Calprotectin was measured by an enzyme-linked immunosorbent assay (ELISA). The cutoff value was defined as mean + 2 standard deviations of HCs. Multivariable logistic regression analysis was used to analyze risk factors. Pearson correlation analysis was used to detect the correlation between calprotectin and other laboratory data. Of the 466 patients included in the study, 281 (60.3%) patients met the 2006 Sydney Revised Classification Criteria; among the latter, 77.2% were patients with primary APS. The mean age was 39.10 ± 13.05 years old, and 77.0% were female. Thirty-eight age- and sex-matched HCs were included in the study. Serum calprotectin levels were increased in aPL-positive patients compared with HCs (649.66 ± 240.79 vs 484.62 ± 149.37 ng/ml, p < 0.001), and were increased in patients with microvascular manifestations compared with patients without (693.03 ± 271.90 vs 639.43 ± 232.06 ng/ml, p = 0.044). The cutoff value was 783.36 ng/ml. Ninety-three patients (20.0%) were positive for calprotectin. Calprotectin positivity was independently associated with microvascular manifestations (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.07-3.36) and platelet count (PLT) < 100 (OR 2.04, 95% CI 1.08-3.88). Age (OR 0.98, 95% CI 0.96-1.00), systemic lupus erythematosus (OR 2.08, 95% CI 1.15-3.75), calprotectin positivity (OR 1.83, 95% CI 1.02-3.26), hypertension (OR 2.73, 95% CI 1.36-5.45), hemolytic anemia (OR 2.66, 95% CI 1.13-6.23), and anti-β2GPI antibodies (OR 2.06, 95% CI 1.11-3.83) could independently predict microvascular manifestations in aPL-positive patients. Serum calprotectin negatively correlated with PLT (R = - 0.101, p = 0.031). Serum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations. Abstract Introduction Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of microvascular manifestations in antiphospholipid antibody (aPL)-positive patients. Methods Consecutive patients with persistent aPL positivity referred to Peking Union Medical College Hospital and age- and sex-matched health controls (HCs) were included. Microvascular manifestations included antiphospholipid syndrome (APS) nephropathy, livedo reticularis, valvular lesions, non-stroke central nervous system manifestations, myocarditis, catastrophic APS, and other microvascular manifestations confirmed by pathology, imaging, or clinical diagnosis. Calprotectin was measured by an enzyme-linked immunosorbent assay (ELISA). The cutoff value was defined as mean + 2 standard deviations of HCs. Multivariable logistic regression analysis was used to analyze risk factors. Pearson correlation analysis was used to detect the correlation between calprotectin and other laboratory data. Results Of the 466 patients included in the study, 281 (60.3%) patients met the 2006 Sydney Revised Classification Criteria; among the latter, 77.2% were patients with primary APS. The mean age was 39.10 ± 13.05 years old, and 77.0% were female. Thirty-eight age- and sex-matched HCs were included in the study. Serum calprotectin levels were increased in aPL-positive patients compared with HCs (649.66 ± 240.79 vs 484.62 ± 149.37 ng/ml, p < 0.001), and were increased in patients with microvascular manifestations compared with patients without (693.03 ± 271.90 vs 639.43 ± 232.06 ng/ml, p = 0.044). The cutoff value was 783.36 ng/ml. Ninety-three patients (20.0%) were positive for calprotectin. Calprotectin positivity was independently associated with microvascular manifestations (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.07–3.36) and platelet count (PLT) < 100 (OR 2.04, 95% CI 1.08–3.88). Age (OR 0.98, 95% CI 0.96–1.00), systemic lupus erythematosus (OR 2.08, 95% CI 1.15–3.75), calprotectin positivity (OR 1.83, 95% CI 1.02–3.26), hypertension (OR 2.73, 95% CI 1.36–5.45), hemolytic anemia (OR 2.66, 95% CI 1.13–6.23), and anti-β2GPI antibodies (OR 2.06, 95% CI 1.11–3.83) could independently predict microvascular manifestations in aPL-positive patients. Serum calprotectin negatively correlated with PLT (R = − 0.101, p = 0.031). Conclusion Serum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations. Introduction Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of microvascular manifestations in antiphospholipid antibody (aPL)-positive patients. Methods Consecutive patients with persistent aPL positivity referred to Peking Union Medical College Hospital and age- and sex-matched health controls (HCs) were included. Microvascular manifestations included antiphospholipid syndrome (APS) nephropathy, livedo reticularis, valvular lesions, non-stroke central nervous system manifestations, myocarditis, catastrophic APS, and other microvascular manifestations confirmed by pathology, imaging, or clinical diagnosis. Calprotectin was measured by an enzyme-linked immunosorbent assay (ELISA). The cutoff value was defined as mean + 2 standard deviations of HCs. Multivariable logistic regression analysis was used to analyze risk factors. Pearson correlation analysis was used to detect the correlation between calprotectin and other laboratory data. Results Of the 466 patients included in the study, 281 (60.3%) patients met the 2006 Sydney Revised Classification Criteria; among the latter, 77.2% were patients with primary APS. The mean age was 39.10 ± 13.05 years old, and 77.0% were female. Thirty-eight age- and sex-matched HCs were included in the study. Serum calprotectin levels were increased in aPL-positive patients compared with HCs (649.66 ± 240.79 vs 484.62 ± 149.37 ng/ml, p < 0.001), and were increased in patients with microvascular manifestations compared with patients without (693.03 ± 271.90 vs 639.43 ± 232.06 ng/ml, p = 0.044). The cutoff value was 783.36 ng/ml. Ninety-three patients (20.0%) were positive for calprotectin. Calprotectin positivity was independently associated with microvascular manifestations (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.07–3.36) and platelet count (PLT) < 100 (OR 2.04, 95% CI 1.08–3.88). Age (OR 0.98, 95% CI 0.96–1.00), systemic lupus erythematosus (OR 2.08, 95% CI 1.15–3.75), calprotectin positivity (OR 1.83, 95% CI 1.02–3.26), hypertension (OR 2.73, 95% CI 1.36–5.45), hemolytic anemia (OR 2.66, 95% CI 1.13–6.23), and anti-β2GPI antibodies (OR 2.06, 95% CI 1.11–3.83) could independently predict microvascular manifestations in aPL-positive patients. Serum calprotectin negatively correlated with PLT ( R = − 0.101, p = 0.031). Conclusion Serum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations. Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of microvascular manifestations in antiphospholipid antibody (aPL)-positive patients.INTRODUCTIONMicrovascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find markers for microvascular manifestations. This study was conducted to explore whether serum calprotectin could be a predictor of microvascular manifestations in antiphospholipid antibody (aPL)-positive patients.Consecutive patients with persistent aPL positivity referred to Peking Union Medical College Hospital and age- and sex-matched health controls (HCs) were included. Microvascular manifestations included antiphospholipid syndrome (APS) nephropathy, livedo reticularis, valvular lesions, non-stroke central nervous system manifestations, myocarditis, catastrophic APS, and other microvascular manifestations confirmed by pathology, imaging, or clinical diagnosis. Calprotectin was measured by an enzyme-linked immunosorbent assay (ELISA). The cutoff value was defined as mean + 2 standard deviations of HCs. Multivariable logistic regression analysis was used to analyze risk factors. Pearson correlation analysis was used to detect the correlation between calprotectin and other laboratory data.METHODSConsecutive patients with persistent aPL positivity referred to Peking Union Medical College Hospital and age- and sex-matched health controls (HCs) were included. Microvascular manifestations included antiphospholipid syndrome (APS) nephropathy, livedo reticularis, valvular lesions, non-stroke central nervous system manifestations, myocarditis, catastrophic APS, and other microvascular manifestations confirmed by pathology, imaging, or clinical diagnosis. Calprotectin was measured by an enzyme-linked immunosorbent assay (ELISA). The cutoff value was defined as mean + 2 standard deviations of HCs. Multivariable logistic regression analysis was used to analyze risk factors. Pearson correlation analysis was used to detect the correlation between calprotectin and other laboratory data.Of the 466 patients included in the study, 281 (60.3%) patients met the 2006 Sydney Revised Classification Criteria; among the latter, 77.2% were patients with primary APS. The mean age was 39.10 ± 13.05 years old, and 77.0% were female. Thirty-eight age- and sex-matched HCs were included in the study. Serum calprotectin levels were increased in aPL-positive patients compared with HCs (649.66 ± 240.79 vs 484.62 ± 149.37 ng/ml, p < 0.001), and were increased in patients with microvascular manifestations compared with patients without (693.03 ± 271.90 vs 639.43 ± 232.06 ng/ml, p = 0.044). The cutoff value was 783.36 ng/ml. Ninety-three patients (20.0%) were positive for calprotectin. Calprotectin positivity was independently associated with microvascular manifestations (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.07-3.36) and platelet count (PLT) < 100 (OR 2.04, 95% CI 1.08-3.88). Age (OR 0.98, 95% CI 0.96-1.00), systemic lupus erythematosus (OR 2.08, 95% CI 1.15-3.75), calprotectin positivity (OR 1.83, 95% CI 1.02-3.26), hypertension (OR 2.73, 95% CI 1.36-5.45), hemolytic anemia (OR 2.66, 95% CI 1.13-6.23), and anti-β2GPI antibodies (OR 2.06, 95% CI 1.11-3.83) could independently predict microvascular manifestations in aPL-positive patients. Serum calprotectin negatively correlated with PLT (R = - 0.101, p = 0.031).RESULTSOf the 466 patients included in the study, 281 (60.3%) patients met the 2006 Sydney Revised Classification Criteria; among the latter, 77.2% were patients with primary APS. The mean age was 39.10 ± 13.05 years old, and 77.0% were female. Thirty-eight age- and sex-matched HCs were included in the study. Serum calprotectin levels were increased in aPL-positive patients compared with HCs (649.66 ± 240.79 vs 484.62 ± 149.37 ng/ml, p < 0.001), and were increased in patients with microvascular manifestations compared with patients without (693.03 ± 271.90 vs 639.43 ± 232.06 ng/ml, p = 0.044). The cutoff value was 783.36 ng/ml. Ninety-three patients (20.0%) were positive for calprotectin. Calprotectin positivity was independently associated with microvascular manifestations (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.07-3.36) and platelet count (PLT) < 100 (OR 2.04, 95% CI 1.08-3.88). Age (OR 0.98, 95% CI 0.96-1.00), systemic lupus erythematosus (OR 2.08, 95% CI 1.15-3.75), calprotectin positivity (OR 1.83, 95% CI 1.02-3.26), hypertension (OR 2.73, 95% CI 1.36-5.45), hemolytic anemia (OR 2.66, 95% CI 1.13-6.23), and anti-β2GPI antibodies (OR 2.06, 95% CI 1.11-3.83) could independently predict microvascular manifestations in aPL-positive patients. Serum calprotectin negatively correlated with PLT (R = - 0.101, p = 0.031).Serum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations.CONCLUSIONSerum calprotectin levels are increased in aPL-positive patients and could be a potential predictor of microvascular manifestations. |
| Author | Huang, Can Tian, Xinping Li, Mengtao Zeng, Xiaofeng Wang, Qian Qi, Wanting Zhao, Yan Zhou, Yangzhong Zhao, Jiuliang Zhao, Yuan |
| Author_xml | – sequence: 1 givenname: Yuan surname: Zhao fullname: Zhao, Yuan organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 2 givenname: Wanting surname: Qi fullname: Qi, Wanting organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 3 givenname: Can surname: Huang fullname: Huang, Can organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 4 givenname: Yangzhong surname: Zhou fullname: Zhou, Yangzhong organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 5 givenname: Qian surname: Wang fullname: Wang, Qian organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 6 givenname: Xinping surname: Tian fullname: Tian, Xinping organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 7 givenname: Mengtao surname: Li fullname: Li, Mengtao email: mengtao.li@cstar.org.cn organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 8 givenname: Yan surname: Zhao fullname: Zhao, Yan organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 9 givenname: Xiaofeng surname: Zeng fullname: Zeng, Xiaofeng organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 10 givenname: Jiuliang orcidid: 0000-0001-9308-2858 surname: Zhao fullname: Zhao, Jiuliang email: zjlpumc@sina.com organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37906398$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ustu1DAUtVARLaU_wAJZYsMmYDvxI8tqxKNSK0YqrK0b56b1KLEHOynq32OaMkhddGH52jrn3Nd5TY5CDEjIW84-csb0p9ww3TQVE3XFmOKsal-QE8FbUylpmqNDrNUxOct5xxjjSihl9CtyXOuWqbo1J-TuGtMy0Q2M-xRndLMPFDIFui2vMHsY6TZh790cE40DvfIuxTvIbhkh0SsIfsA8w-xjyLRwtyUsvEx_-_mWnheF_W3M5Yx-73t6fR_6FCd8Q14OMGY8e7xPyc8vn39svlWX379ebM4vKyelmCujpNSsbbHRgEbWpldMG6lNrVivle4b1HpwKAzwQUg0wg3SCQQ3gOq4rk_JxarbR9jZffITpHsbwduHj5huLKTZuxEtGMG6ukgDQNMZ0YlaCy4QS3bXiKZofVi1yqR-LaVrO_nscBwhYFyyFcZIwQSXskDfP4Hu4pJC6bSgWiaNaKUqqHePqKWbsD-U9287BSBWQJl5zgmHA4Qz-9cFdnWBLS6wDy6wbSGZJyTn1wXNCfz4PLVeqbnkCTeY_pf9DOsP7ALF9Q |
| CitedBy_id | crossref_primary_10_3389_fimmu_2024_1354349 |
| Cites_doi | 10.1016/j.jaut.2022.102813 10.1182/blood-2011-01-333617 10.1002/art.42624 10.1371/journal.ppat.1000639 10.1016/j.chom.2019.05.003 10.1097/CM9.0000000000002128 10.1177/0961203319882506 10.1056/NEJMoa1312890 10.1189/jlb.70.1.130 10.1182/blood.2021014966 10.3748/wjg.v7.i4.460 10.3899/jrheum.181241 10.1074/jbc.272.14.9496 10.1016/j.pharmthera.2016.07.015 10.1016/j.blre.2022.101015 10.1002/art.39656 10.1016/j.thromres.2020.10.010 10.1182/blood-2018-11-882993 10.1111/j.1538-7836.2006.01753.x 10.1155/2013/828354 10.1186/s13075-022-02814-w 10.1002/art.21968 10.1191/0961203303lu394oa 10.3899/jrheum.081302 10.1177/09612033211069762 10.1186/s13075-022-02726-9 10.1007/s11239-020-02324-z 10.2478/rir-2022-0016 10.1007/s11926-014-0494-8 10.3389/fimmu.2021.648881 10.1002/art.41891 10.1111/jth.15047 10.1016/j.semarthrit.2017.12.006 10.2478/rir-2022-0033 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 DOA |
| DOI | 10.1007/s40744-023-00610-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2198-6584 |
| EndPage | 1783 |
| ExternalDocumentID | oai_doaj_org_article_a820b3783aaa4b82b237212ee9e4c424 37906398 10_1007_s40744_023_00610_9 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: Beijing Municipal Science and Technology Commission grantid: Z201100005520022; Z201100005520023; Z201100005520025; Z201100005520026; Z201100005520027 funderid: http://dx.doi.org/10.13039/501100009592 – fundername: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) grantid: 2021-I2M-1-005 – fundername: National High Level Hospital Clinical Research Funding grantid: 2022-PUMCH-B-013; 2022-PUMCH-A-008 – fundername: Key Technology Research and Development Program of Shandong grantid: 2021YFC2501305 funderid: http://dx.doi.org/10.13039/100014103 – fundername: Key Technology Research and Development Program of Shandong grantid: 2021YFC2501305 – fundername: National High Level Hospital Clinical Research Funding grantid: 2022-PUMCH-A-008 – fundername: Beijing Municipal Science and Technology Commission grantid: Z201100005520026 – fundername: Beijing Municipal Science and Technology Commission grantid: Z201100005520027 – fundername: National High Level Hospital Clinical Research Funding grantid: 2022-PUMCH-B-013 – fundername: Beijing Municipal Science and Technology Commission grantid: Z201100005520025 – fundername: Beijing Municipal Science and Technology Commission grantid: Z201100005520022 – fundername: Beijing Municipal Science and Technology Commission grantid: Z201100005520023 |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7RV 7X7 88E 8C1 8FI 8FJ AAKKN ABEEZ ABUWG ACACY ACGFS ACULB ADBBV ADINQ ADRAZ AFGXO AFKRA AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAPOH BCNDV BENPR BKEYQ BPHCQ BVXVI C24 C6C CCPQU EBS EJD FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR ITC KQ8 M1P M48 M~E NAPCQ O9- OK1 PIMPY PQQKQ PROAC PSQYO RPM RSV SISQX SOJ UKHRP ~JE AAYXX CITATION PHGZM PHGZT NPM 7XB 8FK AZQEC COVID DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c552t-86557099e47ae8538d6078578360d767d4e77fce28a1f25e82cf5c2eacfa6b173 |
| IEDL.DBID | M48 |
| ISSN | 2198-6576 |
| IngestDate | Wed Aug 27 01:20:02 EDT 2025 Fri Jul 11 08:27:49 EDT 2025 Fri Jul 25 04:48:17 EDT 2025 Thu Apr 03 06:51:38 EDT 2025 Thu Apr 24 23:01:22 EDT 2025 Tue Jul 01 04:22:54 EDT 2025 Fri Feb 21 02:41:42 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Thrombocytopenia Microcirculation Antiphospholipid antibody Calprotectin |
| Language | English |
| License | 2023. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c552t-86557099e47ae8538d6078578360d767d4e77fce28a1f25e82cf5c2eacfa6b173 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-9308-2858 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1007/s40744-023-00610-9 |
| PMID | 37906398 |
| PQID | 2890582956 |
| PQPubID | 2034668 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a820b3783aaa4b82b237212ee9e4c424 proquest_miscellaneous_2885202155 proquest_journals_2890582956 pubmed_primary_37906398 crossref_primary_10_1007_s40744_023_00610_9 crossref_citationtrail_10_1007_s40744_023_00610_9 springer_journals_10_1007_s40744_023_00610_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-01 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cheshire |
| PublicationPlace_xml | – name: Cheshire – name: England – name: Heidelberg |
| PublicationTitle | Rheumatology and therapy. |
| PublicationTitleAbbrev | Rheumatol Ther |
| PublicationTitleAlternate | Rheumatol Ther |
| PublicationYear | 2023 |
| Publisher | Springer Healthcare Springer Nature B.V Adis, Springer Healthcare |
| Publisher_xml | – name: Springer Healthcare – name: Springer Nature B.V – name: Adis, Springer Healthcare |
| References | You, Zhao, Li, Zeng (CR13) 2022; 3 Radin, Ugolini-Lopes, Sciascia, Andrade (CR32) 2018; 48 Colicchia, Schrottmaier, Perrella (CR24) 2022; 140 Qi, Zhao, Huang (CR4) 2022; 24 CR12 Lood, Tyden, Gullstrand (CR26) 2016; 68 El Hasbani, Saliba, Uthman, Taher (CR30) 2023; 58 Canaud, Bienaime, Tabarin (CR27) 2014; 371 Hu, Li, Xie (CR18) 2021; 12 Erkan (CR6) 2021; 73 Guedon, Catano, Ricard (CR5) 2022; 24 Soyfoo, Roth, Vogl, Pochet, Decaux (CR23) 2009; 36 Pruenster, Vogl, Roth, Sperandio (CR7) 2016; 167 Huang, Zhao, Tian (CR14) 2023; 41 Tektonidou (CR35) 2022; 128 Shi, Giannakopoulos, Yan (CR31) 2006; 54 Barbhaiya, Zuily, Naden (CR2) 2023; 75 Asherson, Cervera, de Groot (CR1) 2003; 12 Sayar, Moll, Isenberg, Cohen (CR3) 2021; 198 Rammes, Roth, Goebeler, Klempt, Hartmann, Sorg (CR20) 1997; 272 Huang, Hu, Zhao (CR33) 2022; 135 Tibble, Bjarnason (CR25) 2001; 7 Li, Zhao, Zhao (CR16) 2019; 46 Xie, Li, Qi (CR15) 2022; 31 Zuo, Zuo, Yalavarthi (CR9) 2021; 51 Artim-Esen, Diz-Kucukkaya, Inanc (CR29) 2015; 17 Devreese, de Groot, de Laat (CR17) 2020; 18 Miyakis, Lockshin, Atsumi (CR19) 2006; 4 Agostinis, Biffi, Garrovo (CR28) 2011; 118 Ruff, Dehner, Kim (CR11) 2019; 26 Jackson, Darbousset, Schoenwaelder (CR10) 2019; 133 Schiopu, Cotoi (CR8) 2013 Sun, Zhao, Zhang (CR34) 2019; 28 Urban, Ermert, Schmid (CR21) 2009; 5 Voganatsi, Panyutich, Miyasaki, Murthy (CR22) 2001; 70 C Hu (610_CR18) 2021; 12 B Artim-Esen (610_CR29) 2015; 17 D Erkan (610_CR6) 2021; 73 C Huang (610_CR14) 2023; 41 M Radin (610_CR32) 2018; 48 SP Jackson (610_CR10) 2019; 133 M Colicchia (610_CR24) 2022; 140 H You (610_CR13) 2022; 3 M Pruenster (610_CR7) 2016; 167 RA Asherson (610_CR1) 2003; 12 CF Urban (610_CR21) 2009; 5 C Huang (610_CR33) 2022; 135 M Barbhaiya (610_CR2) 2023; 75 A Schiopu (610_CR8) 2013 S Miyakis (610_CR19) 2006; 4 A Voganatsi (610_CR22) 2001; 70 G Canaud (610_CR27) 2014; 371 W Qi (610_CR4) 2022; 24 Z Sayar (610_CR3) 2021; 198 JA Tibble (610_CR25) 2001; 7 WE Ruff (610_CR11) 2019; 26 610_CR12 MG Tektonidou (610_CR35) 2022; 128 AF Guedon (610_CR5) 2022; 24 C Li (610_CR16) 2019; 46 Y Sun (610_CR34) 2019; 28 Y Zuo (610_CR9) 2021; 51 C Agostinis (610_CR28) 2011; 118 C Lood (610_CR26) 2016; 68 MS Soyfoo (610_CR23) 2009; 36 Z Xie (610_CR15) 2022; 31 KMJ Devreese (610_CR17) 2020; 18 A Rammes (610_CR20) 1997; 272 T Shi (610_CR31) 2006; 54 G El Hasbani (610_CR30) 2023; 58 |
| References_xml | – volume: 128 year: 2022 ident: CR35 article-title: Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis publication-title: J Autoimmun doi: 10.1016/j.jaut.2022.102813 – volume: 118 start-page: 4231 issue: 15 year: 2011 end-page: 4238 ident: CR28 article-title: In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions publication-title: Blood doi: 10.1182/blood-2011-01-333617 – volume: 75 start-page: 1687 year: 2023 end-page: 1702 ident: CR2 article-title: 2023 ACR/EULAR antiphospholipid syndrome classification criteria publication-title: Arthritis Rheumatol doi: 10.1002/art.42624 – volume: 5 issue: 10 year: 2009 ident: CR21 article-title: Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000639 – volume: 26 start-page: 100.e8 issue: 1 year: 2019 end-page: 113.e8 ident: CR11 article-title: Pathogenic autoreactive T and B cells cross-react with mimotopes expressed by a common human gut commensal to trigger autoimmunity publication-title: Cell Host Microbe doi: 10.1016/j.chom.2019.05.003 – volume: 135 start-page: 2251 issue: 18 year: 2022 end-page: 2252 ident: CR33 article-title: Extra-criteria clinical manifestations of antiphospholipid antibody should not be ignored publication-title: Chin Med J (Engl) doi: 10.1097/CM9.0000000000002128 – ident: CR12 – volume: 28 start-page: 1558 issue: 13 year: 2019 end-page: 1565 ident: CR34 article-title: Clinical characteristics and risk factors of microvascular involvement in primary antiphospholipid syndrome: a longitudinal single-center study in China publication-title: Lupus doi: 10.1177/0961203319882506 – volume: 371 start-page: 303 issue: 4 year: 2014 end-page: 312 ident: CR27 article-title: Inhibition of the mTORC pathway in the antiphospholipid syndrome publication-title: N Engl J Med doi: 10.1056/NEJMoa1312890 – volume: 70 start-page: 130 issue: 1 year: 2001 end-page: 134 ident: CR22 article-title: Mechanism of extracellular release of human neutrophil calprotectin complex publication-title: J Leukoc Biol doi: 10.1189/jlb.70.1.130 – volume: 140 start-page: 2626 issue: 24 year: 2022 end-page: 2643 ident: CR24 article-title: S100A8/A9 drives the formation of procoagulant platelets through GPIbalpha publication-title: Blood doi: 10.1182/blood.2021014966 – volume: 7 start-page: 460 issue: 4 year: 2001 end-page: 465 ident: CR25 article-title: Non-invasive investigation of inflammatory bowel disease publication-title: World J Gastroenterol doi: 10.3748/wjg.v7.i4.460 – volume: 46 start-page: 755 issue: 7 year: 2019 end-page: 756 ident: CR16 article-title: Hepatic infarction caused by antiphospholipid syndrome secondary to systemic lupus erythematosus publication-title: J Rheumatol doi: 10.3899/jrheum.181241 – volume: 272 start-page: 9496 issue: 14 year: 1997 end-page: 9502 ident: CR20 article-title: Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway publication-title: J Biol Chem doi: 10.1074/jbc.272.14.9496 – volume: 167 start-page: 120 year: 2016 end-page: 131 ident: CR7 article-title: S100A8/A9: from basic science to clinical application publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2016.07.015 – volume: 58 year: 2023 ident: CR30 article-title: Hematological manifestations of antiphospholipid syndrome: going beyond thrombosis publication-title: Blood Rev doi: 10.1016/j.blre.2022.101015 – volume: 68 start-page: 1970 issue: 8 year: 2016 end-page: 1980 ident: CR26 article-title: Platelet-derived S100A8/A9 and cardiovascular disease in systemic lupus erythematosus publication-title: Arthritis Rheumatol doi: 10.1002/art.39656 – volume: 198 start-page: 213 year: 2021 end-page: 221 ident: CR3 article-title: Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management publication-title: Thromb Res doi: 10.1016/j.thromres.2020.10.010 – volume: 133 start-page: 906 issue: 9 year: 2019 end-page: 918 ident: CR10 article-title: Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms publication-title: Blood doi: 10.1182/blood-2018-11-882993 – volume: 4 start-page: 295 issue: 2 year: 2006 end-page: 306 ident: CR19 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – year: 2013 ident: CR8 article-title: S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease publication-title: Mediators Inflamm doi: 10.1155/2013/828354 – volume: 24 start-page: 140 issue: 1 year: 2022 ident: CR4 article-title: Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study publication-title: Arthritis Res Ther doi: 10.1186/s13075-022-02814-w – volume: 54 start-page: 2558 issue: 8 year: 2006 end-page: 2567 ident: CR31 article-title: Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V publication-title: Arthritis Rheum doi: 10.1002/art.21968 – volume: 41 start-page: 1017 issue: 5 year: 2023 end-page: 1023 ident: CR14 article-title: Early recognition of catastrophic antiphospholipid syndrome in patients with antiphospholipid syndrome based on a Chinese cohort study publication-title: Clin Exp Rheumatol – volume: 12 start-page: 530 issue: 7 year: 2003 end-page: 534 ident: CR1 article-title: Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines publication-title: Lupus doi: 10.1191/0961203303lu394oa – volume: 36 start-page: 2190 issue: 10 year: 2009 end-page: 2194 ident: CR23 article-title: Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus publication-title: J Rheumatol doi: 10.3899/jrheum.081302 – volume: 31 start-page: 178 issue: 2 year: 2022 end-page: 186 ident: CR15 article-title: Characteristics and risk factors of retinal vasculopathy in antiphospholipid syndrome publication-title: Lupus doi: 10.1177/09612033211069762 – volume: 24 start-page: 33 issue: 1 year: 2022 ident: CR5 article-title: Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study publication-title: Arthritis Res Ther doi: 10.1186/s13075-022-02726-9 – volume: 51 start-page: 446 issue: 2 year: 2021 end-page: 453 ident: CR9 article-title: Neutrophil extracellular traps and thrombosis in COVID-19 publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-020-02324-z – volume: 3 start-page: 93 issue: 2 year: 2022 end-page: 94 ident: CR13 article-title: Recurrent non-stroke central neurologic manifestations in primary antiphospholipid syndrome publication-title: Rheumatol Immunol Res doi: 10.2478/rir-2022-0016 – volume: 17 start-page: 14 issue: 3 year: 2015 ident: CR29 article-title: The significance and management of thrombocytopenia in antiphospholipid syndrome publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-014-0494-8 – volume: 12 year: 2021 ident: CR18 article-title: Comparison of different test systems for the detection of antiphospholipid antibodies in a Chinese cohort publication-title: Front Immunol doi: 10.3389/fimmu.2021.648881 – volume: 73 start-page: 1780 issue: 10 year: 2021 end-page: 1790 ident: CR6 article-title: Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome publication-title: Arthritis Rheumatol doi: 10.1002/art.41891 – volume: 18 start-page: 2828 issue: 11 year: 2020 end-page: 2839 ident: CR17 article-title: Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation publication-title: J Thromb Haemost doi: 10.1111/jth.15047 – volume: 48 start-page: 117 issue: 1 year: 2018 end-page: 120 ident: CR32 article-title: Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2017.12.006 – volume: 12 start-page: 530 issue: 7 year: 2003 ident: 610_CR1 publication-title: Lupus doi: 10.1191/0961203303lu394oa – volume: 118 start-page: 4231 issue: 15 year: 2011 ident: 610_CR28 publication-title: Blood doi: 10.1182/blood-2011-01-333617 – volume: 12 year: 2021 ident: 610_CR18 publication-title: Front Immunol doi: 10.3389/fimmu.2021.648881 – volume: 135 start-page: 2251 issue: 18 year: 2022 ident: 610_CR33 publication-title: Chin Med J (Engl) doi: 10.1097/CM9.0000000000002128 – volume: 28 start-page: 1558 issue: 13 year: 2019 ident: 610_CR34 publication-title: Lupus doi: 10.1177/0961203319882506 – volume: 58 year: 2023 ident: 610_CR30 publication-title: Blood Rev doi: 10.1016/j.blre.2022.101015 – volume: 26 start-page: 100.e8 issue: 1 year: 2019 ident: 610_CR11 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2019.05.003 – volume: 7 start-page: 460 issue: 4 year: 2001 ident: 610_CR25 publication-title: World J Gastroenterol doi: 10.3748/wjg.v7.i4.460 – volume: 46 start-page: 755 issue: 7 year: 2019 ident: 610_CR16 publication-title: J Rheumatol doi: 10.3899/jrheum.181241 – volume: 73 start-page: 1780 issue: 10 year: 2021 ident: 610_CR6 publication-title: Arthritis Rheumatol doi: 10.1002/art.41891 – year: 2013 ident: 610_CR8 publication-title: Mediators Inflamm doi: 10.1155/2013/828354 – volume: 272 start-page: 9496 issue: 14 year: 1997 ident: 610_CR20 publication-title: J Biol Chem doi: 10.1074/jbc.272.14.9496 – volume: 31 start-page: 178 issue: 2 year: 2022 ident: 610_CR15 publication-title: Lupus doi: 10.1177/09612033211069762 – volume: 371 start-page: 303 issue: 4 year: 2014 ident: 610_CR27 publication-title: N Engl J Med doi: 10.1056/NEJMoa1312890 – volume: 17 start-page: 14 issue: 3 year: 2015 ident: 610_CR29 publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-014-0494-8 – volume: 70 start-page: 130 issue: 1 year: 2001 ident: 610_CR22 publication-title: J Leukoc Biol doi: 10.1189/jlb.70.1.130 – volume: 198 start-page: 213 year: 2021 ident: 610_CR3 publication-title: Thromb Res doi: 10.1016/j.thromres.2020.10.010 – volume: 68 start-page: 1970 issue: 8 year: 2016 ident: 610_CR26 publication-title: Arthritis Rheumatol doi: 10.1002/art.39656 – volume: 41 start-page: 1017 issue: 5 year: 2023 ident: 610_CR14 publication-title: Clin Exp Rheumatol – volume: 18 start-page: 2828 issue: 11 year: 2020 ident: 610_CR17 publication-title: J Thromb Haemost doi: 10.1111/jth.15047 – volume: 133 start-page: 906 issue: 9 year: 2019 ident: 610_CR10 publication-title: Blood doi: 10.1182/blood-2018-11-882993 – volume: 24 start-page: 33 issue: 1 year: 2022 ident: 610_CR5 publication-title: Arthritis Res Ther doi: 10.1186/s13075-022-02726-9 – volume: 140 start-page: 2626 issue: 24 year: 2022 ident: 610_CR24 publication-title: Blood doi: 10.1182/blood.2021014966 – volume: 24 start-page: 140 issue: 1 year: 2022 ident: 610_CR4 publication-title: Arthritis Res Ther doi: 10.1186/s13075-022-02814-w – volume: 3 start-page: 93 issue: 2 year: 2022 ident: 610_CR13 publication-title: Rheumatol Immunol Res doi: 10.2478/rir-2022-0016 – volume: 48 start-page: 117 issue: 1 year: 2018 ident: 610_CR32 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2017.12.006 – volume: 36 start-page: 2190 issue: 10 year: 2009 ident: 610_CR23 publication-title: J Rheumatol doi: 10.3899/jrheum.081302 – volume: 4 start-page: 295 issue: 2 year: 2006 ident: 610_CR19 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – volume: 54 start-page: 2558 issue: 8 year: 2006 ident: 610_CR31 publication-title: Arthritis Rheum doi: 10.1002/art.21968 – volume: 167 start-page: 120 year: 2016 ident: 610_CR7 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2016.07.015 – volume: 128 year: 2022 ident: 610_CR35 publication-title: J Autoimmun doi: 10.1016/j.jaut.2022.102813 – volume: 5 issue: 10 year: 2009 ident: 610_CR21 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000639 – ident: 610_CR12 doi: 10.2478/rir-2022-0033 – volume: 75 start-page: 1687 year: 2023 ident: 610_CR2 publication-title: Arthritis Rheumatol doi: 10.1002/art.42624 – volume: 51 start-page: 446 issue: 2 year: 2021 ident: 610_CR9 publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-020-02324-z |
| SSID | ssj0001626687 |
| Score | 2.2543685 |
| Snippet | Introduction
Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is... Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is important to find... IntroductionMicrovascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it is... Abstract Introduction Microvascular manifestations constitute a subtype of antiphospholipid syndrome, and those patients have relatively poor prognoses, so it... |
| SourceID | doaj proquest pubmed crossref springer |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1769 |
| SubjectTerms | Antiphospholipid antibody Autoimmune diseases Biomarkers Calprotectin Diagnostic tests Family Medicine General Practice Internal Medicine Medicine Medicine & Public Health Microcirculation Original Research Orthopedics Quality of Life Research Rheumatology Thrombocytopenia Vein & artery diseases |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQqDwCBRmJG1jsOn4e24qqQlq0ElTqzZo4tlhpya6a3f5-ZpxsKOJ14ZBDEsdKMjOZbzIznxl742fe-VlsRPLRCCXTXPgmg0DflFowFgEddSMvPpnLK_XxWl_fWeqLasIGeuDhxb0HdFFNbV0NAKpxspE1Bi0yJZ9UVLIwgaLPuxNMlb8riNNNWR0PLdJRfYcZO2ZK3xxGMUoJdFeCXPhM-J-8UiHv_x3i_CVbWpzQxUP2YESP_HS460fsXuqO2S3a-_4bP4f1SLqw6jj0HPgS9zq04DVf3lA-BsNrvsl8QTV4hwpUvgCqbumHjHzP8drlQLXac_pHy09xhu3XTY_berVdtfzzyHHwmF1dfPhyfinG5RRE1FruBLWgWgSESVlI6KVdaxAf6NLG0VpjW5WszTFJB_MsdXIyZh0lfpkzmGZu6yfsqNt06RnjWebU6CxbAKPcTENrFE5p6gjU6ltXbH54nSGOXOO05MU6TCzJRQQBRRCKCIKv2Nvpmu3AtPHX0WckpWkksWSXA6g7YdSd8C_dqdjJQcZhNN0-UOZVO4lxY8VeT6fR6CiTAl3a7GmM05LQkq7Y00E3pjuprSfY5yr27qAsPyb_8wM9_x8P9ILdl6TVpdzmhB3tbvbpJYKmXfOq2Md3s_oOpQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZguXBBi3gFFmQkbmDROn7lhJYVqxVSUSVYqTfLcWyoVJLStPv7mXGcVAjYQw9tHSvJzHg-e2a-IeRNNatMNfM1C5VXTPAwZ1UdHQPfFBqnNAA6rEZefFFX1-LzSq7ygVuf0yrHNTEt1E3n8Yz8PQbEpOEA5z9sfzHsGoXR1dxC4y65h9RlqNV6pY9nLIDWVeqRB3ZpMMtD5bqZVD0HexkhGDgtho58xqo_fFOi8P8X7vwrZppc0eUpeZAxJD0fhP6Q3AntI3IDVn_4SS_cJlMvrFvqeuroEr61YMcbutxhVAY22bSLdIGZeGMeKl04zHHph7h8T-Ha5UC42lM8qaXnMMP2R9fDZ7Perhv6NTMdPCbXl5--XVyx3FSBeSn5nmEhqgZYGIR2AXy1aRSgBJmKORqtdCOC1tEHbtw8chkM91F6DutzdKqe6_IJOWm7NjwjNPIYahl545wSZiZdowRMqUrvsOC3LMh8fJ3WZ8ZxbHyxsRNXchKBBRHYJAJbFeTtdM124Nu4dfRHlNI0Ermy0w_d7rvNpmcdgJy6hAd0zona8JqXsO3lIcA78IKLgpyNMrbZgHt7VLeCvJ7-BtPDeIprQ3fAMUZyxEyyIE8H3ZjupNQVgj9TkHejshwn__8DPb_9Xl6Q-9jufkinOSMn-90hvARQtK9fJc3_DS-mBqs priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEB_0BPFF_LZ6SgTfNLhN89XHc_E4hJUFPbi3kKYJLux1l-uuf78zbbaHego-9KHtNLSdTOeXzsxvAN7Ws9rWs9DwWAfNpYglr5vkOfqm2HptENBRNfLiiz47l58v1EWmyaFamN_i9x96XHBIydGzcPK2M17fhjuqrAy1aZjr-fX_FETmeuiHhzZoKaND5xqZm4f5xQ8NdP03Ycw_4qOD2zl9APczXmQno4Ifwq3YPYK7ixwRfww_0Nj3l2zu15lxYdUx3zPPlrjXofmu2fKKpHFtzTaJLSgB75B-yhaeUlv6MRzfM7x2OfKs9ox-0LITHGH7fdPjtl5tVy37mgkOnsD56adv8zOeeynwoJTYcao_NYgGozQ-oou2rUZwoIYajtZo08poTApRWF8moaIVIakg8LOcvG5KUz2Fo27TxefAkkixUUm03mtpZ8q3WuKQugqe6nyrAsrDm3UhE41Tv4u1myiSB2041IYbtOHqAt5N12xHmo1_Sn8khU2SRJE9HMCZ47LFOY_YpqnwAb33srGiERWudkWM-A6CFLKA44O6Xbbb3lHYVVmBi8YC3kyn0eIojOK7uNmTjFWCoJIq4Nk4TaY7qUxNmM8W8P4wb64H__sDvfg_8Zdwj7rej1k1x3C0u9rHV4iNds3rwSh-Ak_PAoU priority: 102 providerName: Springer Nature |
| Title | Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome |
| URI | https://link.springer.com/article/10.1007/s40744-023-00610-9 https://www.ncbi.nlm.nih.gov/pubmed/37906398 https://www.proquest.com/docview/2890582956 https://www.proquest.com/docview/2885202155 https://doaj.org/article/a820b3783aaa4b82b237212ee9e4c424 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9NAEB_uA-ReRPEr3llW8E0jzWa_8iByF-44hB5FLfQtbJKNV4hpbdpD_3tntklE7PmQQJrN0OzMZH6zOx8Ab5JxYpJxkYcuKVQouIvCJK9siLbJlVZpBHSUjTy5Udcz8Wku5wfQtzvqJrDd69pRP6nZun7_88evj6jwH4Y0OHRKhAjR-oRkkcdhcgjHaJk0dTSYdHDfr7kgele-Zx7qqaGoD9Xl0ewncwIPYp2QETd_mS1f3X8fJP1nO9VbqatH8LCDl-x8Jw-P4cA1T-AOPwjb7yy1dVeVYdEw2zLLpnjVoIrXbLqmDRv0v9myYhMK0utDVNnEUvhLu9uybxk-O93VYm0ZLeKyc6Swul22eNSL1aJkX7oiCE9hdnX5Nb0Ou34LYSEl34SUo6oRMTqhrUMzbkqFAEL6PI9SK10Kp3VVOG5sVHHpDC8qWXD8dFdW5ZGOn8FRs2zcC2AVr1wuK15aq4QZS1sqgSRVXFjKBY4DiPrpzIquGDn1xKizoYyy50aG3Mg8N7IkgLfDM6tdKY7_jr4gLg0jqYy2_2G5_pZ1WplZxD95jC9orRW54TmP0SPmzuEcFIKLAM56Hme9aGa0NSsNR8cygNfDbdRK2mqxjVtuaYyRnOCUDOD5TjaGf9KLVADvemH5Q_z-F3p5L6FTOOEktT7I5gyONuute4VQaZOP4FDPNZ5NGo3g-OLyZvoZr1Iu6KzSkV-CGHkt-Q2bZQ-E |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaW5QAXBOIVWMBIcAKLxrEd54DQUlh12e2qErvS3ozjOFCpJKVpQfwpfiMzzqNCwN72kENTx0o845lvPC9CnmWjTGcjlzOfOcUE9zHL8tIy0E2-sCoFQIfZyNMTNTkTH87l-Q751efCYFhlLxODoC5qh2fkr9AhJjUHOP9m-Y1h1yj0rvYtNFq2OPI_f4DJ1rw-fAf0fc75wfvT8YR1XQWYk5KvGWZipoCLvEitB2WlCwVqUoZshiJVaSF8mpbOc23jkkuvuSul4yCgSqvyOE1g3ivkqkhga2Jm-jjenumAdaBCTz6QAxqjSlSXpxOy9cB2EoKBkmQIHEYs-0MXhpYB_8K5f_log-o7uEludJiV7rdMdovs-Oo2-Q5SZvOVju2iK_Uwr6htqKUz-FWB3FjQ2Qq9QGDU07qkU4z86-Ne6dRiTE3TxgE0FJ6dtQVeG4onw3QfZlh-qRu4FvPlvKAfu8oKd8jZpSz3XbJb1ZW_T2jJS5_LkhfWKqFH0hZKwJQqcRYTjJOIxP1yGtdVOMdGGwsz1GYOJDBAAhNIYLKIvBieWbb1PS4c_RapNIzE2tzhRr36bLqtbiyAqjyBD7TWilzznCdgZnPvYQ2c4CIiez2NTScwGrNl74g8Hf6GrY7-G1v5eoNjtOSI0WRE7rW8MbxJkmYINnVEXvbMsp38_x_04OJ3eUKuTU6nx-b48OToIbnOkXdDKM8e2V2vNv4RALJ1_jjsAko-Xfa2-w122UK2 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkBAvCMRXYICR4AmsNY7tOA8IjY5qY3SqBJP2ZpzEhkolKU0L4l_jr-PO-agQsLc99KGtbSW-893vfF-EPMtGmc5GRc5cVigmuItZlnvLQDe50qoUAB1mI09P1dGZeHcuz3fIrz4XBsMqe5kYBHVZF3hHvo8OMak5wPl934VFzA4nr5ffGHaQQk9r306jZZET9_MHmG_Nq-NDoPVzzidvP46PWNdhgBVS8jXDrMwUMJITqXWguHSpQGXKkNlQpiothUtTXziubey5dJoXXhYchJW3Ko_TBNa9Qq6mCczALPVxvL3fAUtBhf58IBM0RpioLmcnZO6BHSUEA4XJEESMWPaHXgztA_6Fef_y1wY1OLlJbnT4lR60DHeL7LjqNvkOEmfzlY7toiv7MK-obailM_hWgQxZ0NkKPUJg4NPa0ylGAfYxsHRqMb6maWMCGgpzZ22x14biLTE9gBWWX-oGPov5cl7SD12VhTvk7FK2-y7ZrerK3SfUc-9y6XlprRJ6JG2pBCypksJisnESkbjfTlN01c6x6cbCDHWaAwkMkMAEEpgsIi-GOcu21seFo98glYaRWKc7_FCvPpvu2BsLACtH7rDWilzznCdgcnPnYA8KwUVE9noam054NGbL6hF5OvwNxx59ObZy9QbHaMkRr8mI3Gt5Y3iSJM0QeOqIvOyZZbv4_1_owcXP8oRcgwNn3h-fnjwk1zmybojq2SO769XGPQJsts4fh0NAyafLPnW_AbpwRuw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Calprotectin+as+a+Potential+Predictor+of+Microvascular+Manifestations+in+Patients+with+Antiphospholipid+Syndrome&rft.jtitle=Rheumatology+and+therapy.&rft.au=Zhao%2C+Yuan&rft.au=Qi%2C+Wanting&rft.au=Huang%2C+Can&rft.au=Zhou%2C+Yangzhong&rft.date=2023-12-01&rft.issn=2198-6576&rft.volume=10&rft.issue=6&rft.spage=1769&rft_id=info:doi/10.1007%2Fs40744-023-00610-9&rft_id=info%3Apmid%2F37906398&rft.externalDocID=37906398 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2198-6576&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2198-6576&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2198-6576&client=summon |